49 filings
8-K
NRIX
Nurix Therapeutics Inc
21 May 24
Submission of Matters to a Vote of Security Holders
7:06am
8-K
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
8-K
NRIX
Nurix Therapeutics Inc
10 Apr 24
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
7:02am
8-K
NRIX
Nurix Therapeutics Inc
9 Apr 24
Other Events
1:17pm
8-K
NRIX
Nurix Therapeutics Inc
11 Mar 24
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
7:02am
8-K
85dpkb ug48r61
15 Feb 24
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
4:01pm
8-K
ahhdbefu f2l3vsq9pw
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
5vvjim6
11 Dec 23
Other Events
12:03pm
8-K
x2zx3ay lsj7b
13 Nov 23
Regulation FD Disclosure
7:01am
8-K
f3r8co euzlvb
1 Nov 23
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
4:02pm
8-K
n5foqyvc
12 Oct 23
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:03pm
8-K
7xqty6js9x3ct1k
7 Sep 23
Entry into a Material Definitive Agreement
7:02am
8-K
65p67xy80nwy1
13 Jul 23
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:18pm
8-K
9hqjoc2h1vpy6jpxefpg
4 May 23
Submission of Matters to a Vote of Security Holders
4:09pm
8-K
zwhjvreoj6iy69a0m
13 Apr 23
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:02pm
8-K
bfuai7su8aqotze
10 Apr 23
Departure of Directors or Certain Officers
7:16am
8-K
0gbw1c8
13 Mar 23
Other Events
5:26pm
8-K
n2kqf3ko
9 Feb 23
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update
4:16pm
8-K
8874 xqmqg
9 Jan 23
Other Events
7:01am
8-K
dmhjwgq7w 39dincqr8k
16 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:07pm